Insights
Search Results
Client Highlights
2.26.26
Wilson Sonsini Advises Eventus on Majority Investment by Terminus Capital Partners
On February 26, 2026, Terminus Capital Partners (TCP), a growth‑oriented private equity firm focused on majority investments in B2B software companies, and Eventus, a leading provider of comprehensive, at-scale trade surveillance and financial risk solutions, announced that TCP has acquired majority control in Eventus, positioning the firm for accelerated geographical expansion and growth in its product offerings. Wilson Sonsini Goodrich & Rosati advised Eventus on the transaction.
Client Highlights
2.13.26
Firm Advises Microchip Technology on Offering of $900 Million of Convertible Senior Notes
On February 11, 2026, Microchip Technology completed an offering of $900 million aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Microchip had granted to the initial purchasers to purchase up to an additional $100 million of notes. In connection with the offering, Microchip entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and other financial institutions.
Client Highlights
3.26.25
Wilson Sonsini Advises Lumata Health on $23 Million Series B
On March 5, 2025, Lumata Health, a leader in personalized support for patients with vision-threatening chronic eye diseases, announced that it has raised $23 million in Series B funding to accelerate its mission of eliminating preventable vision loss, bringing its total raised since inception to $36 million. The round was co-led by LRVHealth, McKesson Ventures, and Cencora Ventures, with participation from existing investors, including Cortado Ventures. The investment will enable Lumata to meet growing demand and further enhance the data-driven technology powering its patient adherence solutions.
Client Highlights
3.25.25
Wilson Sonsini Advises Microchip on Offering of $1.48 Billion of Depositary Shares
On March 25, 2025, Microchip Technology completed a mandatory convertible preferred stock offering of $1.48 billion of depositary shares, each representing a 1/20th interest in a share of 7.50% Series A Mandatory Convertible Preferred Stock, in an underwritten public offering. The offering amount included the exercise in full of the over-allotment option that Microchip had granted to the underwriters to purchase up to an additional $135 million of depositary shares. In connection with the offering, Microchip entered into privately negotiated capped call transactions with one or more of the underwriters and other financial institutions. Microchip is one of the first technology companies to use this mandatory convertible preferred stock structure with a capped call feature.
Client Highlights
12.16.24
Wilson Sonsini Represents Microchip in $2 Billion Investment Grade Notes Offering
On December 16, 2024, Microchip Technology Incorporated (Microchip) priced an offering of (i) $1 billion in aggregate principal amount of its 4.900 percent senior notes due 2028 (2028 notes), and (ii) $1 billion in aggregate principal amount of its 5.050 percent senior notes due 2030 (2030 notes, together with 2028 notes, “the notes”). The notes are and will be guaranteed by each of Microchip's existing and future subsidiaries that is or becomes an obligor under Microchip's existing senior credit facilities. The sale of the notes closed on December 16, 2024. Microchip intends to use the net proceeds from the sale of the notes to repay its senior term loan facility, a portion of the debt outstanding under its commercial paper program and the payment of fees and expenses related to the offering of the notes.
Client Highlights
12.13.24
Wilson Sonsini Advises Lumos Pharma on Tender Offer and Merger with Double Point Ventures
On December 12, 2024, Lumos Pharma, a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures (DPV) announced the successful completion the previously announced tender offer for Lumos Pharma's shares, with 75.62 percent of shares tendered. The purchase price of $4.25 per share represents a total equity value of approximately $38 million. Following the acceptance of the shares offered in the tender, DPV successfully acquired enough shares of Lumos Pharma's common stock to finalize the merger. Wilson Sonsini Goodrich & Rosati advised Lumos Pharma on the transaction.
Newsletters
10.03.24
Focus on Fintech – Q2 2024
In the latest edition, our attorneys discuss updates and developments from federal regulators, including those related to cryptocurrencies, cybersecurity in financial markets, and the intersection of fintech and AI. They also discuss rulemakings and proposals from the SEC, the CFTC, and FinCEN, and examine a federal appellate court’s recent decision to vacate SEC rules governing private fund advisers. Finally, they conclude with a survey of consumer protection developments, which discusses recent policy initiatives from the CFPB, and a novel payments law passed by the Illinois legislature.
Client Highlights
6.21.24
Wilson Sonsini Advises Ascentage Pharma on HK$585.77 Million (US$75 Million) Equity Investment from Takeda International in Connection with the Exclusive Global License for HQP1351 (olverembatinib)
Ascentage Pharma Group International (Ascentage Pharma) and Takeda Pharmaceuticals International AG (Takeda International) entered into an exclusive option agreement on June 14, 2024, where Takeda International is granted with an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib), a core drug candidate of Ascentage Pharma. In connection with such exclusive global arrangement, Ascentage Pharma and Takeda International also entered into a securities purchase agreement, pursuant to which Takeda International made a HK$585.77 million (US$75 million) equity investment in Ascentage Pharma to subscribe 24,307,322 shares of Ascentage Pharma at a purchase price of HK$24.09850 per share. The closing of such equity investment took place on June 20, 2024.
Newsletters
5.29.24
Focus on Fintech – Q1 2024
In this latest edition, our attorneys discuss updates and developments from federal regulators, including those related to the intersection of fintech and artificial intelligence, cryptocurrency and virtual currency updates, and consumer protection. They also discuss rule updates from the SEC and FinCEN, and examine the continued scrutiny by the FDIC, the FTC, and FINRA on fintech marketing. Finally, this issue concludes with a state law round-up, which discusses Kansas’ and Wisconsin’s adoption of a licensing framework for earned wage access providers and New York’s new surcharge law.
Client Highlights
3.08.24
Wilson Sonsini Represents Microchip in $1 Billion Investment Grade Notes Offering
On March 5, 2024, Microchip Technology Incorporated (Microchip) priced an offering of $1 billion in aggregate principal amount of its 5.050% senior notes due 2029 (the notes). The notes are and will be guaranteed by each of Microchip’s existing and future subsidiaries that is or becomes an obligor under Microchip’s existing senior credit facilities. The sale of the notes closed on March 7, 2024. Microchip intends to use the net proceeds from the sale of the notes to repay a portion of the debt outstanding under its commercial paper program and the payment of fees and expenses related to the offering of the notes.